Evidence map›Paper›PMID 22670883›Full record

ArticleAmyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases2012

Electrical impedance myography as a biomarker to assess ALS progression.

Seward B Rutkove, James B Caress, Michael S Cartwright, Ted M Burns, Judy Warder, William S David, Namita Goyal, Nicholas J Maragakis, Lora Clawson, Michael Benatar and 7 more

Registry-linked trialOpen access · greenAbstract readMulticenter Study
In one paragraph

Article in Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06491732 (Electrical Impedance Myography Via the Myolex mScan as an ALS Biomarker), which is not on this map. Cited by 83 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 2 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06491732 recruitingnot on this mapstarted 2025, after this paper: background citation

Electrical Impedance Myography Via the Myolex mScan as an ALS Biomarker

TypeobservationalSponsorBeth Israel Deaconess Medical CenterRan2025 to 2027Enrolled80ConditionsAmyotrophic Lateral SclerosisArmsElectrical Impedance Myography
3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 142 citations in OpenAlex.

  1. Pooled it
  2. The evolving role of surface electromyography in amyotrophic lateral sclerosis: A systematic review.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2020
    Pooled it
  3. Trial
  4. Inter-session reliability of electrical impedance myography in children in a clinical trial setting.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2015
    Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 1 country.

Seward B RutkoveDepartment of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA. srutkove@bidmc.harvard.edu
James B Caress
Michael S Cartwright
Ted M Burns
Judy Warder
William S David
Namita Goyal
Nicholas J Maragakis
Lora Clawson
Michael Benatar
Sharon Usher
Khema R Sharma
Shiva Gautam
Pushpa Narayanaswami
Elizabeth M Raynor
Mary Lou Watson
Jeremy M Shefner
Harvard University Press · USSUNY Upstate Medical University · USUniversity of Miami · USUniversity of Virginia · USWake Forest University · USBeth Israel Deaconess Medical Center · USJohns Hopkins Bayview Medical Center · USJohns Hopkins University · USMassachusetts General Hospital · USUniversity of South Florida · US

Funding

Innovative Ultrasound Technology in Neuromuscular DiseaseK24NS060951 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI RUTKOVE, SEWARD B. · 2008 to 2017
$1.5M
NINDS NIH HHS K24 NS060951
6 · The paper itself

Abstract

Electrical impedance myography (EIM), a non-invasive, electrophysiological technique, has preliminarily shown value as an ALS biomarker. Here we perform a multicenter study to further assess EIM's potential for tracking ALS. ALS patients were enrolled across eight sites. Each subject underwent EIM, handheld dynamometry (HHD), and the ALS Functional Rating Scale-revised (ALSFRS-R) regularly. Techniques were compared by assessing the coefficient of variation (CoV) in the rate of decline and each technique's correlation to survival. Results showed that in the 60 patients followed for one year, EIM phase measured from the most rapidly progressing muscle in each patient had a CoV in the rate of decline of 0.62, compared to HHD (0.82) and the ALSFRS-R (0.74). Restricting the measurements to the first six months gave a CoV of 0.55 for EIM, 0.93 for HHD, and 0.84 for ALSFRS-R. For both time-periods, all three measures correlated with survival. Based on these data, a six-month clinical trial designed to detect a 20% treatment effect with 80% power using EIM would require only 95 patients/arm compared to the ALSFRS-R, which would require 220 subjects/arm. In conclusion, EIM can serve as a useful ALS biomarker that offers the prospect of greatly accelerating phase 2 clinical trials.

Indexed as

Electric ImpedanceAdolescentAdultAgedAged, 80 and overAmyotrophic Lateral SclerosisClinical Trials as TopicDisease ProgressionFemaleHumansMaleMiddle AgedMuscle, SkeletalMyographySurvival RateTime Factors

Identifiers

PMID22670883
PMCPMC3422377
OpenAlexW2082397844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.